Advanced search
Publication Cover
Journal of Chemotherapy Volume 14, 2002 - Issue 2
Submit an article Journal homepage
21
Views
10
CrossRef citations to date
0
Altmetric
Articles

Combined Low-Dose Intravesical Immunotherapy (BCG + Interferon a-2b) in the Management of Superficial Transitional Cell Carcinoma of the Urinary Bladder: A Five-Year Follow-Up

N.K. Mohanty
,
V. Malhotra
,
R.L. Nayak
&
R.P. Arora
Pages 194-197 | Published online: 18 Jul 2013

References

  • American Cancer Society - Cancer Facts & Figures 1990. American Cancer Society, USA.
  • Herr HW, Landone VP. Intravesical therapy for superfi-cial bladder cancer. American Urological Association (AUA) update series 1989; Vol. VIII, Lesson 12.
  • Hency NM, Proppe K, Pront JR GR. Intravesical blad-der cancer. Tumor configuration lymphatic invasion and sur-vival. J Urol 1983; 130: 895.
  • Jong WH de, Steerenbery PA, Ruitenberg EJ. Bacillus Calmette Guerein. BCG and its use for cancer immunothera-py. In: Tumor Immunology Mechanisms, Diagnosis, Therapy. Otter W den, Ruitenberg EJ, eds. Amsterdam: Elsevier, 1987.
  • Torti FM, Lum BL. Superficial bladder cancer: risk of recurrences and potential role for Interferon therapy. Cancer 1987; 59: 613.
  • Isaac A, Lindermann J. Virus interference, the interfer-on. Proc R Doc Land (Biol) 1957; 147: 258–267.
  • Mohanty NK, Gulati P, Saxena S. Role of interferon a-2b in prevention of superficial TCC recurrences. Urol Int 1997; 59: 194–196.
  • Mohanty NK, Mandal MN, Sinha AN, et al. Intravesical BCG + interferon a-2b in prevention of recurrences in TCC of urinary bladder. Int J Urol 2000; 16 (2): 128–133.
  • Morales A, Eidinger D, Bruce AW, et al. Intracavity BCG in treatment of superficial bladder tumors. J Urol 1976; 116: 180–183.
  • Zlotta R, Drowart A, Van Vooren, et al. The need of a maintenance BCG therapy is suggested by the inability of intravesical BCG to promote a long term systemic immune T-cell activation. J Urol 1997; 157 (suppl): 383.
  • Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. Uro Clin North Am 1992; 19 (3): 573–580.
  • Torti FM, Shortliffe LD, William RD, et al. Alpha inter-feron in superficial bladder cancer - a Northern California Oncology group study. J Clin Oncol 1988; 6: 476.
  • Stricker P, Pryor K, Nicholson T, et al. Bacillus Cal-mette Guerin and intravesical interferon a-2b in patients with superficial bladder cancer. Urology 1996; 48: 957–962.
  • Bercovich D. BCG vs BCG + interferon a-2b recombi-nata nei tumori superficiali della vescica. Arch Ital Urol 1995; 67: 257–260.
  • O'Donell HA. Experimental and clinical evidence of enhancement of BCG efficacy by adding interferon a-2b. J Urol 1997; 157: 382.
  • Engelmann U, Knopf HJ, Graff J. Interferon a-2b instillation prophylaxis in superficial bladder cancer. Prospective, controlled three armed trial, project Grebochum: Interferon and superficial bladder cancer. Anti Cancer Drugs 1992; (suppl 3): 33-37.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.